Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.2 EUR | -0.64% | +4.03% | -3.73% |
Apr. 17 | Orapi SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 12 | Orapi: Groupe Paredes holds almost 90% of the capital | CF |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The stock, which is currently worth 2024 to 0.42 times its sales, is clearly overvalued in comparison with peers.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.73% | 43.5M | - | ||
-1.20% | 66.01B | A- | ||
+47.62% | 41.76B | B | ||
+15.99% | 38.66B | B | ||
+4.25% | 32.28B | A- | ||
+8.78% | 19.57B | B- | ||
+12.32% | 16.77B | C+ | ||
+17.69% | 15.08B | B- | ||
+8.31% | 14.83B | B | ||
-14.59% | 13.95B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ORAP Stock
- Ratings ORAPI